CARA
Cara Therapeutics Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Market Cap: 53.9 Million
Primary Exchange: NASDAQ
Website: http://www.caratherapeutics.com/
Shares Outstanding: 54.5 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.79260297208746
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1058 trading days
From: 2017-06-28 To: 2021-04-05
Lowest Point:
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
Cara's Second Half Catalyst Has The Potential To Change The Scope Of The Biotech Forever
via: SeekingAlpha at 2019-06-11 12:53:54:000
Cara Therapeutics ( CARA ) announced that it had achieved positive phase 3 results from its phase 3 KALM-1 study treating hemodialysis patients with CKD associated pruritus using KORSUVA injection. There is another catalyst due in the 2nd half of 2019, which are results from an identical lat… read more...
Cara Therapeutics: Positive Phase III KALM-1 Results Make Me Feel Calm
via: SeekingAlpha at 2019-06-10 07:10:56:000
Investment Thesis Cara Therapeutics ( CARA ) recently reported top-line results of its Phase III KALM-1 U.S. clinical study of KORSUVA Injection in Hemodialysis Patients with moderate-to-severe Pruritus. Following the positive phase III KALM-1 clinical trial results, the stock price surged… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|